Characterisation of two novel leukaemia specific antigens, PASD1 and SSX2IP, as targets for AML immunotherapy

Project: Research

Project Details

StatusFinished
Effective start/end date1/01/200531/10/2006

Funding

  • Blood Cancer UK: £75,769.00